Back to List View Graph View

Hemagglutinin

Hemagglutinin (HA) is the major surface glycoprotein of influenza viruses and one of the principal antigenic determinants targeted by the host immune system.

Where the papers sit

19 papers from the last 6 months study hemagglutinin directly · updated from PubMed 16 Nov 2026

Those 19 are all about one subject.

  • Broad Influenza Vaccine Development

    Broad protection against influenza is driving vaccine design toward conserved hemagglutinin epitopes and consensus immunogens rather than strain-matched responses alone. Neutralizing and bispecific antibodies, anti-idiotypic mimics, and COBRA HAs target shared antigenic sites across influenza A and B. mRNA, DNA, lipid nanoparticle, outer membrane vesicle, microneedle, and nano-adjuvant platforms aim to improve dose efficiency and mucosal as well as systemic immunity. Evidence spans mouse and primate protection, preclinical safety, and a phase 2 seasonal mRNA vaccine study. Antigenic variation and durable breadth remain open challenges.

    19 papers

Papers

The 19 papers from the last 6 months that study hemagglutinin directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Broad Influenza Vaccine Development (19)
  1. Dual-target chemical profiling of anti-influenza multi-components from Isatidis Radix via direct binding to neuraminidase and hemagglutinin. Bioorganic chemistry · 1 Oct 2026 PMID 42822352
  2. A nano-adjuvant platform potentiates immunity for potent mucosal and systemic defense against influenza. Journal of controlled release : official journal of the Controlled Release Society · 15 Sept 2026 PMID 42744201
  3. Anti-idiotypic antibodies as molecular mimics of conserved influenza hemagglutinin epitopes. Protein science : a publication of the Protein Society · 15 Sept 2026 PMID 42742346
  4. Preclinical toxicity and immunogenicity of a quadrivalent recombinant influenza hemagglutinin vaccine (SCVC101) in rhesus monkeys. Vaccine · 13 Sept 2026 PMID 42732725
  5. Consensus H3N2 HA immunogens incorporating key antigenic mutations elicit broad-spectrum neutralizing responses. Emerging microbes & infections · 7 Sept 2026 PMID 42703780
  6. Broadly reactive antibodies against influenza B virus hemagglutinin neutralize and protect through distinct structural mechanisms. Journal of virology · 4 Sept 2026 PMID 42696304
  7. Linear DNA expression cassette encapsulated in lipid nanoparticles confers complete protection against influenza A virus in mice. mSphere · 4 Sept 2026 PMID 42695687
  8. Nanoemulsion adjuvanted COBRA HA vaccine enhances protective antibody titers against H1N1 and H3N2 influenza viruses. Human vaccines & immunotherapeutics · 3 Sept 2026 PMID 42691282
  9. Mannose-functionalized thermoresponsive microneedles for enhanced antigen delivery and immune activation. Journal of materials chemistry. B · 27 Aug 2026 PMID 42657667
  10. A bispecific antibody targeting conserved hemagglutinin epitopes confers broad protection against H7 avian influenza and accelerates viral clearance via localized respiratory delivery. Emerging microbes & infections · 19 Aug 2026 PMID 42617142
  11. Neutralizing and protective monoclonal antibodies identify antigenic sites in influenza H7 hemagglutinin and select for amino acid substitutions rarely observed at the global level. Microbiology spectrum · 6 Aug 2026 PMID 42560073
  12. Identification and computational analysis of B-cell epitopes on the hemagglutinin protein of the H3N2 influenza virus. Archives of microbiology · 5 Aug 2026 PMID 42554770
  13. Capless self-amplifying mRNA vaccine induces dose-sparing protective immunity against HPAI clade 2.3.4.4 H5 virus in mice. Molecular therapy : the journal of the American Society of Gene Therapy · 30 Jul 2026 PMID 42528137
  14. Optimized seasonal influenza mRNA vaccine compositions demonstrate safety and enhanced immunogenicity in a phase 2 study. Human vaccines & immunotherapeutics · 13 Jul 2026 PMID 42441816
  15. Intranasal influenza vaccination using an outer membrane vesicle platform. Vaccine · 26 Jun 2026 PMID 42361782
  16. A subunit vaccine for multiple respiratory viruses. Science advances · 26 Jun 2026 PMID 42361166
  17. Emergence of an antigenically drifted and reassorted influenza B virus at the end of the 2024-25 influenza season. mBio · 22 Jun 2026 PMID 42328860
  18. BECC-adjuvanted hemagglutinin influenza vaccine promotes enhanced immunogenicity and protective efficacy. Vaccine · 31 May 2026 PMID 42218860
  19. Conjugate vaccine technology enhances responses to influenza virus. Vaccine · 22 May 2026 PMID 42172691

By study type

Clinical trials (1)
  1. Optimized seasonal influenza mRNA vaccine compositions demonstrate safety and enhanced immunogenicity in a phase 2 study. Human vaccines & immunotherapeutics · 13 Jul 2026 PMID 42441816
Human data, design not indexed (2)
  1. Dual-target chemical profiling of anti-influenza multi-components from Isatidis Radix via direct binding to neuraminidase and hemagglutinin. Bioorganic chemistry · 1 Oct 2026 PMID 42822352
  2. Emergence of an antigenically drifted and reassorted influenza B virus at the end of the 2024-25 influenza season. mBio · 22 Jun 2026 PMID 42328860
Preclinical: animal, cell and lab studies (16)
  1. A nano-adjuvant platform potentiates immunity for potent mucosal and systemic defense against influenza. Journal of controlled release : official journal of the Controlled Release Society · 15 Sept 2026 PMID 42744201
  2. Anti-idiotypic antibodies as molecular mimics of conserved influenza hemagglutinin epitopes. Protein science : a publication of the Protein Society · 15 Sept 2026 PMID 42742346
  3. Preclinical toxicity and immunogenicity of a quadrivalent recombinant influenza hemagglutinin vaccine (SCVC101) in rhesus monkeys. Vaccine · 13 Sept 2026 PMID 42732725
  4. Consensus H3N2 HA immunogens incorporating key antigenic mutations elicit broad-spectrum neutralizing responses. Emerging microbes & infections · 7 Sept 2026 PMID 42703780
  5. Broadly reactive antibodies against influenza B virus hemagglutinin neutralize and protect through distinct structural mechanisms. Journal of virology · 4 Sept 2026 PMID 42696304
  6. Linear DNA expression cassette encapsulated in lipid nanoparticles confers complete protection against influenza A virus in mice. mSphere · 4 Sept 2026 PMID 42695687
  7. Nanoemulsion adjuvanted COBRA HA vaccine enhances protective antibody titers against H1N1 and H3N2 influenza viruses. Human vaccines & immunotherapeutics · 3 Sept 2026 PMID 42691282
  8. Mannose-functionalized thermoresponsive microneedles for enhanced antigen delivery and immune activation. Journal of materials chemistry. B · 27 Aug 2026 PMID 42657667
  9. A bispecific antibody targeting conserved hemagglutinin epitopes confers broad protection against H7 avian influenza and accelerates viral clearance via localized respiratory delivery. Emerging microbes & infections · 19 Aug 2026 PMID 42617142
  10. Neutralizing and protective monoclonal antibodies identify antigenic sites in influenza H7 hemagglutinin and select for amino acid substitutions rarely observed at the global level. Microbiology spectrum · 6 Aug 2026 PMID 42560073
  11. Identification and computational analysis of B-cell epitopes on the hemagglutinin protein of the H3N2 influenza virus. Archives of microbiology · 5 Aug 2026 PMID 42554770
  12. Capless self-amplifying mRNA vaccine induces dose-sparing protective immunity against HPAI clade 2.3.4.4 H5 virus in mice. Molecular therapy : the journal of the American Society of Gene Therapy · 30 Jul 2026 PMID 42528137
  13. Intranasal influenza vaccination using an outer membrane vesicle platform. Vaccine · 26 Jun 2026 PMID 42361782
  14. A subunit vaccine for multiple respiratory viruses. Science advances · 26 Jun 2026 PMID 42361166
  15. BECC-adjuvanted hemagglutinin influenza vaccine promotes enhanced immunogenicity and protective efficacy. Vaccine · 31 May 2026 PMID 42218860
  16. Conjugate vaccine technology enhances responses to influenza virus. Vaccine · 22 May 2026 PMID 42172691